Blinatumomab, a monovalent CD3 and CD19 BiTE, was the first T-cell engager to receive FDA approval in 2014 for the treatment of acute lymphoblastic leukemia [48]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.